Intensity Therapeutics Inc (INTS) FinancialsINTSIntensity Therapeutics Inc

Evaluating the bottom line, Intensity Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -195.88%, provide a clear picture of how effectively INTS converts its operational activities into shareholder value.

In the context of the broader market, INTS competes directly with industry leaders such as PASG and GDTC. With a market capitalization of $9.90M, it holds a significant position in the sector. When comparing efficiency, INTS's gross margin of N/A stands against PASG's N/A and GDTC's 1.81%. Such benchmarking helps identify whether Intensity Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Intensity Therapeutics has reported zero revenue for the last several quarters and has a negative net income, with losses increasing to $3 million in Q2 2026. The current ratio is healthy at 5.00, indicating liquidity, but the overall financial outlook remains bleak.